| Day 3: Tuesday, September 25, 2012 |
|
| 6:30 |
AM |
Networking Breakfast |
|
| 7:30 |
| Welcome: Partnership and Collaboration Announcements |
|
| 7:45 |
|
KEYNOTE:
Centers for Medicare and Medicaid Innovation (CMMI) Challenge Update: News from the Front
- Deliver better care at lower costs through continuous process improvement
- Identify, validate and scale innovative models to provide all beneficiaries with a seamless care experience
- Ensure patients receive the right care, at the right time, in the right setting—every time
Moderator: Edward Horton, MD, Joslin Diabetes Center
Jim Hester, PhD, Centers for Medicare and Medicaid Innovation (CMMI)
|
|
| 8:30 – 12:00 |
SPOTLIGHT
Clinical Technology Breakthroughs
Moderator: Sachin H. Jain, MD, MBA, Merck |
|
| 8:30 |
|
The Artificial Pancreas—A Holy Grail for Type 1 Diabetes?
- Is this the next best thing to a diabetes cure?
- What are the risks of an artificial pancreas if not properly designed?
Henry Anhalt, DO, Animas Corporation
|
|
| 9:00 |
|
Surgical “Cures” For Diabetes?
- Duodenal-jejunal bypass for type 2 diabetes sparks a metabolic change, causing blood sugar levels to drop and seeming to cure diabetes
- What are the clinical and financial implications of this “cure”?
Philip Schauer, MD, Cleveland Clinic
David Cummings, MD, University of Washington
|
|
| 9:30 |
|
Break |
|
| 9:45 |
|
Stopping Before You Start:
New Technologies for Risk Identification and Screening
- How recent findings can improve diabetes risk prediction through metabolite levels
- Identify those at highest risk of developing diabetes with new technologies to start preventive measures early
Robert E. Gerszten, MD, Massachusetts General Hospital
David VanAvermaete, VeraLight
|
|
| 10:15 |
|
Microchip-Based Implants for Managing Diabetes:
How, Why and What about Safety and Security?
- Roll out microchip technology, benefits and considerations
- Evaluate clinician and patient data needs
- Discuss security challenges and possible approaches
Robert Farra, MicroCHIPS
Kevin Fu, PhD, UMASS; University of Michigan
|
|
| 10:45 |
|
The Quantified Self on Steroids:
Innovation in Devices, Pumps and Monitors
- How effective is technology for diabetes management?
- What is the future of technology in type 1 diabetes?
Howard Wolpert, MD, Joslin Diabetes Center
|
|
| 11:15 |
|
Clinical Applications in Diabetes Population Health:
The Good, the Bad and the Ugly
- Evaluate the impact of clinical diabetes applications on A1C and LDL testing rates and laboratory values
- Is participation in diabetes population health programs associated with appropriate clinical control of A1C and LDL values?
- Do members of all ages benefit from participation in diabetes population health programs?
- Discuss future applications for diabetes in population health management from a joint venture
Moderator: Martin J. Abrahamson, MD, FACP, Joslin Diabetes Center
Terry Golash, MD, Aetna
James L. Holly, MD, Southeastern Texas Medical Association (SETMA)
Brandon Savage, MD, Caradigm
|
|
| 12:00 |
PM |
Challenge Grant Announcements and Private Funding Opportunities
- Foster radical rethinking of diabetes control approaches and impact measures given the scale of the epidemic
- Diabetes Innovation Challenge: Create a contest shaped by “public crowdsourcing” for the best innovations to help people living with diabetes
- Challenge grants for patient engagement technologies
- Innovation in philanthropy: Supporting pioneering projects that bring fresh thinking and unconventional approaches to bear on the mostpressing health and health care problems
- More!
Wil Yu, US Department of Health and Human Services (HHS)
Patricia Doykos, Bristol-Myers Squibb Foundation
Angela Moskow, Sanofi US
Brian C. Quinn, PhD, Robert Wood Johnson Foundation
|
|
| 1:00 |
|
Next Steps, Follow-up Plans and Adjourn
John L. Brooks III, Joslin Diabetes Center |
